TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma

BACKGROUND: The standard treatment for patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC) is definitive chemoradiotherapy (CRT) using 5-FU plus cisplatin. However, complete response (CR) rates are low at 11–25%, resulting in 9–10 months of median overall survival (...

Descripción completa

Detalles Bibliográficos
Autores principales: Bando, Hideaki, Kotani, Daisuke, Tsushima, Takahiro, Hara, Hiroki, Kadowaki, Shigenori, Kato, Ken, Chin, Keisho, Yamaguchi, Kensei, Kageyama, Shun-ichiro, Hojo, Hidehiro, Nakamura, Masaki, Tachibana, Hidenobu, Wakabayashi, Masashi, Fukutani, Miki, Togashi, Yosuke, Fuse, Nozomu, Nishikawa, Hiroyoshi, Kojima, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168951/
https://www.ncbi.nlm.nih.gov/pubmed/32312286
http://dx.doi.org/10.1186/s12885-020-06716-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168951/
https://www.ncbi.nlm.nih.gov/pubmed/32312286
http://dx.doi.org/10.1186/s12885-020-06716-5

Ejemplares similares